Slide 1: Papulopustular (acneiform) rash--The acneiform eruption typically occurs during the first weeks in the vast majority of patients receiving EGFRI therapy. Patients develop erythematous papules and pustules over the scalp, face, upper chest, and back. This eruption is occasionally asymptomatic, but is most often associated with variable symptoms of itching, pain, or burning. The rash peaks in severity at 4 to 6 weeks after EGFRI initiation and typically resolves by week 12 or 16 of therapy. Long term sequelae, such as residual erythema and hyperpigmentation, can last for months to years.[1, 2] Image Source: Shivani V Tripathi, MD and Milan J. Anadkat, MD.